[Immunoscintigraphy, an aid to the oncologist--the Rennes experience in using anti-CEA, anti-CA 19.9 monoclonal antibodies and radiolabelled OC-125].
Immunoscintigraphy is steadily asserting itself as a valuable method in the localization of malignant tumours, alongside other imaging techniques. A monoclonal antibody specific to one or several tumour cell lines is used. The antibody is labelled with a gamma emitter radioisotope and so that it can be detected in vivo. We have evaluated three monoclonal antibodies (F(ab')2 fragments): a mixture of anti-CEA and anti-19.9 antibodies in the investigation of colorectal carcinoma and the antibody OC-125 in ovarian cancer. In our experience, it appears that pelvic recurrence is the best indication for immunoscintigraphy. Antibodies can apparently be safely used in man. We noted no side-effect following the injection of anti-CEA, anti 19.9 and OC-125.
Herry
J Y
JY
Centre Régional de Lutte contre le Cancer, CHR Pontchaillou, Rennes.
Bourguet
P
P
Kerbrat
P
P
Le Prise
E
E
Ben Hassel
M
M
Gedouin
D
D
Richier
J L
JL
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D003110:Colonic Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D007158:Immunologic Techniques; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology*; D010386:Pelvic Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology* / Q000473:pathology; D011877:Radionuclide Imaging
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D002272:Carcinoembryonic Antigen
L'immunoscintigraphie, une aide pour le cancérologue--expérience rennaise de l'utilisation des anticorps monoclonaux anti-ACE, anti-CA 19.9 et OC-125 radiomarqués.